Emily Kaiser

Videos

Dilsher Dhoot, MD, discusses the post hoc analysis of the Copernicus and Galileo trials, which investigated if a delay in treatment would affect visual acuity gains or change in anatomy.

Copernicus and Galileo trials: Effect of time since diagnosis on BCVA outcomes in CRVO

Aleksandra Rachitskaya, MD, discussed the Phase 3 Archway end-of-trial results for the investigation of the Port Delivery System with ranibizumab in neovascular AMD.

Phase 3 Archway end-of-trial results: Port Delivery System is noninferior to monthly ranibizumab

Richard Rosen, MD, shares insights on how imaging can capture hyalocytes and their movement without the use of dyes.

Morphologic features of vitreous cortex hyalocyte captured with OCT

Articles

An end-of-week review of retina news and stories from June 18 to June 24.

This week in retina: June 18-June 24

Sheryl brings a wealth of editorial experience to MJH Life Sciences’ Eye Care Network, having engaged with the readers and the greater ophthalmic community of 

for more than 20 years. As Group Editorial Director, Sheryl’s purview extends across the print and digital network of 

Ophthalmology Times, Ophthalmology Times Europe, Modern Retina 

 Prior to ophthalmology, Sheryl previously covered the fields of audiology and confectionery science/technology/manufacturing.

Sheryl is also passionate about the mission, vision and values of Ophthalmic World Leaders (OWL) and recently completed her term on its Board of Directors. She continues to volunteer as Editor-in-Chief of the organization’s 

Magazine. In 2013, she was honored with the group’s inaugural Rising Star Award.

In addition, she has served as a judge for 

 Health Care Heroes Awards program as well as the Jesse H. Neal National Business Journalism Awards.

Steven Yeh, MD, provides a brief overview of available therapies for noninfectious uveitis and uveitis macular edema.

Expanding the therapeutic arsenal for noninfectious uveitis, uveitic macular edema

David Boyer, MD, discusses the Phase 3 investigation for OPT-302 combination therapy for wet AMD.

Phase 3 investigation of OPT-302 combination therapy assess superiority in mean BCVA over anti-VEGF-A monotherapy

The study assesses retinal blood biomarkers using a new prototype OCT, aiming to measure retinal biomarkers such as blood flow volume, average velocity, and vessel diameter with a new prototype.

Measuring retinal blood flow biomarkers using OCT Doppler

In the study, the faricimab molecule, which is a combined anti-Ang2 and anti-VEGF, performed better than the aflibercept drug in many different ways. Rishi P. Singh, MD, FASRS, summarizes some of these key findings.

YOSEMITE and RHINE trials yield durability, retinal fluid reduction, DME resolution with faricimab

Biogen and Samsung Bioepis announce the launch of ranibizumab-nuna and detail when the ophthalmic biosimilar will be available for retina specialists.

First FDA-approved ophthalmic biosimilar ranibizumab-nuna launches in the United States

Yasha S. Modi, MD, discusses his best tips and tricks for finding and diagnosing infectious uveitis.